Portfolio Companies News
February 22, 2019Modus announces First Cohort Dosed ...
STOCKHOLM, SWEDEN – 22 February 2019: Modus Therapeutics AB, a company developing innovative treatments for patients with high unmet medical needs and a focus on sickle cell disease (SCD), announces that the first cohort has been successfully dosed in its Phase 1, Single Ascending Dose Study to Ex... read more
February 22, 2019BONESUPPORT – Publication of a cl...
Lund, Sweden, 08.00 CET, 22 February 2019 – BONESUPPORT, an emerging leader in orthobiologics for the management of bone voids, today announces the publication of new data on antibiotic release from CERAMENT® V in a clinical study. The study ‘Vancomycin elution from a biphasic ceramic bone... read more
February 22, 2019Oncopeptides Year-end Report 2018
Summary of Q4 Financial overview October 1 – December 31, 2018 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 111.4 M (loss: 66.2) Loss per share, before and after dilution, was 2.53 (loss: 1.68) SEK On December 31 cash and cash equivalents amounted to SEK 375... read more
February 21, 2019Rainier Therapeutics to Participate...
SAN LEANDRO, Calif., February 21, 2019 — Rainier Therapeutics, Inc., a privately-held clinical stage drug development company, today announced that Scott Myers, Chairman and Chief Executive Officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 2... read more
February 20, 2019BONESUPPORT HOLDING AB (publ) – I...
Lund, Sweden, 08.00 CET, 20 February 2019 – BONESUPPORT HOLDING AB (publ) -listed on Nasdaq Stockholm - an emerging leader in Orthobiologics for the management of bone voids, invites to a conference call at 10.00 am on 27 February in connection of the Full Year Report 2018, which is publish... read more
February 18, 2019Q4 2018 General Market Overview
Since the start in 1996, HealthCap funds have invested in 113 portfolio companies.
42 of the portfolio companies have been taken public on nine different markets.
25 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 7 companies with a valuation of USD 1 billion or more and 35 companies with a valuation of SEK 1 billion or more.